| Entry |
|
|---|
| Name |
Ruplizumab (USAN/INN) |
|---|
| Efficacy |
Antithrombocytopenia, Immunosuppressant, Anti-CD154 antibody, Anti-CD40 ligand antibody |
|---|
| Type |
Monoclonal antibody |
|---|
| Comment |
Treatment of immune thrombocytopenic purpura and systemic lupus erythematosus
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04514 | Cell adhesion molecule (CAM) interaction |
| hsa04660 | T cell receptor signaling pathway |
|
|---|
| Brite |
Target-based classification of drugs [BR:br08310]
Signaling molecules and receptors
Cytokines
Tumor necrosis factors
TNFSF5 (CD154)
D05777 Ruplizumab (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
